{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:19:26Z","timestamp":1763018366531,"version":"3.41.0"},"reference-count":109,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Sarcoidosis is a granulomatous disease with the potential of multiple organ system involvement and its etiology remains unknown. Cardiac involvement is associated with worse clinical outcome, and has been reported to be 20\u201330% in white and as high as 58% in Japanese populations with sarcoidosis. Clinical manifestations of cardiac sarcoidosis highly depend on the extent and location of granulomatous inflammation. The most frequent presentations include heart block, tachyarrhythmia, or heart failure. Endomyocardial biopsy is the most specific diagnostic test, but has poor sensitivity due to often patchy involvement. The diagnosis of cardiac sarcoidosis remains challenging due to nonspecific imaging findings. Both <jats:sup>18<\/jats:sup>F-fluorodeoxyglucose-positron emission tomography (FDG-PET) and cardiac magnetic resonance imaging can be used to evaluate cardiac sarcoidosis, but evaluate different stages of the disease process. FDG-PET detects metabolically active inflammatory cells while cardiac magnetic resonance imaging with late gadolinium enhancement reveals areas of myocardial necrosis and fibrosis. Aggressive therapy of symptomatic cardiac sarcoidosis is often sought due to the high risk of sudden death and\/or progression to heart failure. Prednisone 20\u201340\u2009mg a day is the recommended initial treatment. In refractory or severe cases, higher doses of prednisone, 1\u20131.5\u2009mg\/kg\/d (or its equivalent) and addition of a steroid-sparing agent have been utilized. Methotrexate is added most commonly. Long-term improvement has been reported with the use of a combination of weekly methotrexate and prednisone versus prednisone alone. After initiation of treatment, a cardiac FDG-PET scan may be performed 2\u20133 months later to assess treatment response.<\/jats:p>","DOI":"10.1097\/crd.0000000000000400","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T15:14:02Z","timestamp":1623856442000},"page":"28-35","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Sarcoid Heart Disease: Review of Current Knowledge"],"prefix":"10.1097","volume":"31","author":[{"given":"Chengyue","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliya","family":"Gandrabur","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cardiology, Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia Y.","family":"Ash","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mayocp.2015.10.024","article-title":"Epidemiology of sarcoidosis 1946-2013: a population-based study.","volume":"91","author":"Ungprasert","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archinte.1929.00140050098009","article-title":"Boeck\u2019s sarcoid: report of a case with visceral involvement.","volume":"44","author":"Bernstein","year":"1929","journal-title":"Arch Intern Med"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/01.CIR.58.6.1204","article-title":"Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.","volume":"58","author":"Silverman","year":"1978","journal-title":"Circulation"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"e4518","DOI":"10.1097\/MD.0000000000004518","article-title":"Prevalence of cardiac sarcoidosis in white population: a case-control study: proposal for a novel risk index based on commonly available tests.","volume":"95","author":"Martusewicz-Boros","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/heartjnl-2015-307877","article-title":"Diagnosis and treatment of cardiac sarcoidosis.","volume":"102","author":"Kusano","year":"2016","journal-title":"Heart"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","article-title":"Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study.","volume":"131","author":"Kandolin","year":"2015","journal-title":"Circulation"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2796.2011.02396.x","article-title":"Diagnosing isolated cardiac sarcoidosis.","volume":"270","author":"Kandolin","year":"2011","journal-title":"J Intern Med"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s12350-016-0658-1","article-title":"Isolated cardiac sarcoidosis: a focused review of an under-recognized entity.","volume":"25","author":"Okada","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"R9-20250619","first-page":"50","article-title":"Cardiac sarcoidosis-state of the art review.","volume":"6","author":"Hulten","year":"2016","journal-title":"Cardiovasc Diagn Ther"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jce.12401","article-title":"Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults.","volume":"25","author":"Nery","year":"2014","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0002-9343(77)90121-8","article-title":"Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11).","volume":"63","author":"Roberts","year":"1977","journal-title":"Am J Med"},{"key":"R12-20250619","first-page":"220","article-title":"Sarcoidosis in northern Israel; clinical characteristics of 120 patients.","volume":"19","author":"Yigla","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"suppl D","key":"R13-20250619","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/12.suppl_D.26","article-title":"Sarcoid heart disease\u2013results of follow-up investigations.","volume":"12","author":"Schaedel","year":"1991","journal-title":"Eur Heart J"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1161\/CIRCULATIONAHA.109.851352","article-title":"Detection of myocardial damage in patients with sarcoidosis.","volume":"120","author":"Patel","year":"2009","journal-title":"Circulation"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1540-8167.2008.01417.x","article-title":"The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities.","volume":"20","author":"Soejima","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","article-title":"JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis- Digest Version.","volume":"83","author":"Terasaki","year":"2019","journal-title":"Circ J"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02072359","article-title":"Recent trends in cardiac sarcoidosis research in Japan.","volume":"1","author":"Sekiguchi","year":"1985","journal-title":"Heart Vessels Suppl"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.amjcard.2013.03.027","article-title":"Predictors of cardiac sarcoidosis using commonly available cardiac studies.","volume":"112","author":"Freeman","year":"2013","journal-title":"Am J Cardiol"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/000456328902600102","article-title":"Serum angiotensin converting enzyme in sarcoidosis\u2013its value in present clinical practice.","volume":"26","author":"Studdy","year":"1989","journal-title":"Ann Clin Biochem"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis.","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"N Engl J Med"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.intimp.2015.01.015","article-title":"Conventional markers in determination of activity of sarcoidosis.","volume":"25","author":"Gungor","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.amjcard.2015.06.021","article-title":"Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis.","volume":"116","author":"Kandolin","year":"2015","journal-title":"Am J Cardiol"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1253\/circj.71.1545","article-title":"Enhanced expression of myeloid-related protein complex (MRP8\/14) in macrophages and multinucleated giant cells in granulomas of patients with active cardiac sarcoidosis.","volume":"71","author":"Terasaki","year":"2007","journal-title":"Circ J"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1536\/ihj.17-695","article-title":"A multiple biomarker approach in patients with cardiac sarcoidosis.","volume":"59","author":"Kiko","year":"2018","journal-title":"Int Heart J"},{"key":"R26-20250619","first-page":"27","article-title":"Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis.","volume":"27","author":"Handa","year":"2010","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2303\/jecho.5.1","article-title":"Cardiac sarcoidosis: what can we know from echocardiography?","volume":"5","author":"Yamano","year":"2007","journal-title":"J Echocardiog"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"E138","DOI":"10.1111\/echo.12536","article-title":"Cardiac sarcoid: a chameleon masquerading as hypertrophic cardiomyopathy and dilated cardiomyopathy in the same patient.","volume":"31","author":"Agarwal","year":"2014","journal-title":"Echocardiography"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4070\/kcj.2011.41.6.313","article-title":"Prevalence of echocardiographic features suggesting cardiac sarcoidosis in patients with pacemaker or implantable cardiac defibrillator.","volume":"41","author":"Sun","year":"2011","journal-title":"Korean Circ J"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1536\/ihj.25.499","article-title":"Echocardiography in sarcoidosis.","volume":"25","author":"Gregor","year":"1984","journal-title":"Jpn Heart J"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"906.e9","DOI":"10.1016\/j.echo.2007.01.009","article-title":"Cardiac sarcoidosis presenting as mitral regurgitation.","volume":"20","author":"Cross","year":"2007","journal-title":"J Am Soc Echocardiogr"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jcmg.2016.11.019","article-title":"Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis.","volume":"10","author":"Kouranos","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1378\/chest.07-2784","article-title":"Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing.","volume":"133","author":"Mehta","year":"2008","journal-title":"Chest"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1532-429X-15-51","article-title":"Guidelines and protocols for cardiovascular magnetic resonance in children and adults with congenital heart disease: SCMR expert consensus group on congenital heart disease.","volume":"15","author":"Fratz","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12968-020-00607-1","article-title":"Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update.","volume":"22","author":"Kramer","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jcmg.2012.10.021","article-title":"CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis.","volume":"6","author":"Greulich","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/MCP.0b013e32832ea4c7","article-title":"Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies.","volume":"15","author":"Sharma","year":"2009","journal-title":"Curr Opin Pulm Med"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/eurjhf\/hfr099","article-title":"Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study.","volume":"13","author":"Patel","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jacc.2005.01.047","article-title":"Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis.","volume":"45","author":"Smedema","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.14-0139","article-title":"Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation.","volume":"146","author":"Nagai","year":"2014","journal-title":"Chest"},{"key":"R41-20250619","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jjcc.2012.08.002","article-title":"Delayed enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in patients with cardiac sarcoidosis.","volume":"60","author":"Shafee","year":"2012","journal-title":"J Cardiol"},{"key":"R42-20250619","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/heartjnl-2013-305187","article-title":"Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis.","volume":"100","author":"Ise","year":"2014","journal-title":"Heart"},{"key":"R43-20250619","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1378\/chest.122.6.1895","article-title":"Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study.","volume":"122","author":"Vignaux","year":"2002","journal-title":"Chest"},{"key":"R44-20250619","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12350-009-9179-5","article-title":"Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: a randomized controlled trial.","volume":"17","author":"Cheng","year":"2010","journal-title":"J Nucl Cardiol"},{"key":"R45-20250619","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2967\/jnumed.108.055616","article-title":"Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET\/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation.","volume":"50","author":"Wykrzykowska","year":"2009","journal-title":"J Nucl Med"},{"key":"R46-20250619","doi-asserted-by":"crossref","first-page":"W151","DOI":"10.2214\/AJR.07.2409","article-title":"Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet.","volume":"190","author":"Williams","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"R47-20250619","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1095-0397(01)00062-0","article-title":"Reduction of myocardial 2-deoxy-2-[18F]fluoro-D-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction.","volume":"4","author":"Lum","year":"2002","journal-title":"Mol Imaging Biol"},{"key":"R48-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2191-219X-4-1","article-title":"Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis.","volume":"4","author":"Morooka","year":"2014","journal-title":"EJNMMI Res"},{"key":"R49-20250619","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/eurheartj\/ehi180","article-title":"Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis.","volume":"26","author":"Ishimaru","year":"2005","journal-title":"Eur Heart J"},{"key":"R50-20250619","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1172\/JCI115780","article-title":"Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo.","volume":"89","author":"Nuutila","year":"1992","journal-title":"J Clin Invest"},{"key":"R51-20250619","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00259-011-1832-y","article-title":"(1)(8)F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis.","volume":"38","author":"Ohira","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"R52-20250619","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s12350-019-01755-3","article-title":"Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.","volume":"26","author":"Kumita","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"R53-20250619","first-page":"124","article-title":"Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C.","volume":"45","author":"Paik","year":"2004","journal-title":"J Nucl Med"},{"key":"R54-20250619","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0002-9343(01)00677-5","article-title":"Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging.","volume":"110","author":"Shimada","year":"2001","journal-title":"Am J Med"},{"key":"R55-20250619","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00259-015-3181-8","article-title":"Comparison of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis.","volume":"43","author":"Ohira","year":"2016","journal-title":"Eur J Nuclear Med Mol Imaging."},{"key":"R56-20250619","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.hrthm.2015.06.032","article-title":"Comparison of cardiac MRI and 18F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complete heart block.","volume":"12","author":"Orii","year":"2015","journal-title":"Heart Rhythm"},{"key":"R57-20250619","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12350-012-9653-3","article-title":"Clinical value of a high-fat and low-carbohydrate diet before FDG-PET\/CT for evaluation of patients with suspected cardiac sarcoidosis.","volume":"20","author":"Soussan","year":"2013","journal-title":"J Nucl Cardiol"},{"key":"R58-20250619","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2967\/jnumed.111.090662","article-title":"The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience.","volume":"53","author":"Youssef","year":"2012","journal-title":"J Nucl Med"},{"key":"R59-20250619","first-page":"1571","article-title":"Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis.","volume":"47","author":"Nishiyama","year":"2006","journal-title":"J Nucl Med"},{"key":"R60-20250619","first-page":"1030","article-title":"Identification of cardiac sarcoidosis with (13)N-NH(3)\/(18)F-FDG PET.","volume":"44","author":"Yamagishi","year":"2003","journal-title":"J Nucl Med"},{"key":"R61-20250619","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s12350-009-9110-0","article-title":"Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis.","volume":"16","author":"Langah","year":"2009","journal-title":"J Nucl Cardiol"},{"key":"R62-20250619","first-page":"1989","article-title":"Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis.","volume":"45","author":"Okumura","year":"2004","journal-title":"J Nucl Med"},{"key":"R63-20250619","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00259-007-0650-8","article-title":"Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis.","volume":"35","author":"Ohira","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R64-20250619","doi-asserted-by":"crossref","first-page":"e008975","DOI":"10.1161\/CIRCIMAGING.118.008975","article-title":"Diagnostic accuracy of advanced imaging in cardiac sarcoidosis.","volume":"12","author":"Divakaran","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"R65-20250619","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1007\/s12350-019-01770-4","article-title":"A new era of imaging for diagnosis and management of cardiac sarcoidosis: hybrid cardiac magnetic resonance imaging and positron emission tomography.","volume":"26","author":"Ahluwalia","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"R66-20250619","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cardfail.2019.02.018","article-title":"Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis.","volume":"25","author":"Ning","year":"2019","journal-title":"J Card Fail"},{"key":"R67-20250619","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000047316","article-title":"Technetium-99m sestamibi\/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis.","volume":"94","author":"Eguchi","year":"2000","journal-title":"Cardiology"},{"key":"R68-20250619","first-page":"1675","article-title":"Myocardial sarcoidosis. Clinical value of technetium-99m sestamibi tomoscintigraphy.","volume":"106","author":"Le Guludec","year":"1994","journal-title":"Chest"},{"key":"R69-20250619","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1148\/rg.2020200068","article-title":"Radionuclide imaging of cardiac amyloidosis and sarcoidosis: roles and characteristics of various tracers.","volume":"40","author":"Hotta","year":"2020","journal-title":"Radiographics"},{"key":"R70-20250619","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2106\/JBJS.15.00898","article-title":"The accuracy of imaging techniques in the assessment of periprosthetic hip infection: a systematic review and meta-analysis.","volume":"98","author":"Verberne","year":"2016","journal-title":"J Bone Joint Surg Am"},{"key":"R71-20250619","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/bmb\/ldv033","article-title":"Advances in radionuclide imaging of cardiac sarcoidosis.","volume":"115","author":"Kouranos","year":"2015","journal-title":"Br Med Bull"},{"key":"R72-20250619","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2967\/jnumed.112.115121","article-title":"Advanced imaging of cardiac sarcoidosis.","volume":"55","author":"Schatka","year":"2014","journal-title":"J Nucl Med"},{"key":"R73-20250619","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s12149-007-0064-5","article-title":"Usefulness of 67Ga SPECT and integrated low-dose CT scanning (SPECT\/CT) in the diagnosis of cardiac sarcoidosis.","volume":"21","author":"Momose","year":"2007","journal-title":"Ann Nucl Med"},{"key":"R74-20250619","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jchf.2014.03.015","article-title":"Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis.","volume":"2","author":"Liang","year":"2014","journal-title":"JACC Heart Fail"},{"key":"R75-20250619","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2011.0296","article-title":"Current status of endomyocardial biopsy.","volume":"86","author":"From","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"R76-20250619","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/hrt.57.3.256","article-title":"Sarcoidosis: a pattern of clinical and morphological presentation.","volume":"57","author":"Valantine","year":"1987","journal-title":"Br Heart J"},{"key":"R77-20250619","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5858\/2009-0274-RA.1","article-title":"Cardiac sarcoidosis: a pathology-focused review.","volume":"134","author":"Lagana","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"R78-20250619","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-2007-970332","article-title":"Pathology of sarcoidosis.","volume":"28","author":"Rosen","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"key":"R79-20250619","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/path.1700790126","article-title":"The nature and origin of Schaumann bodies.","volume":"79","author":"Williams","year":"1960","journal-title":"J Pathol Bacteriol"},{"key":"R80-20250619","first-page":"167","article-title":"Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations.","volume":"119","author":"Perry","year":"1995","journal-title":"Arch Pathol Lab Med"},{"key":"R81-20250619","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.cjca.2013.02.004","article-title":"Corticosteroid therapy for cardiac sarcoidosis: a systematic review.","volume":"29","author":"Sadek","year":"2013","journal-title":"Can J Cardiol"},{"key":"R82-20250619","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1378\/chest.11-0263","article-title":"Management of cardiac sarcoidosis in the United States: a Delphi study.","volume":"141","author":"Hamzeh","year":"2012","journal-title":"Chest"},{"key":"R83-20250619","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone.","volume":"88","author":"Yazaki","year":"2001","journal-title":"Am J Cardiol"},{"key":"R84-20250619","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.acvd.2016.12.014","article-title":"Cardiac sarcoidosis: diagnosis, therapeutic management and prognostic factors.","volume":"110","author":"Chapelon-Abric","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"R85-20250619","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S192922","article-title":"Refractory sarcoidosis: a review.","volume":"16","author":"El Jammal","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"R86-20250619","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1055\/s-0034-1376889","article-title":"Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment.","volume":"35","author":"Lynch","year":"2014","journal-title":"Semin Respir Crit Care Med"},{"key":"R87-20250619","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.2169\/internalmedicine.53.3120","article-title":"Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions.","volume":"53","author":"Nagai","year":"2014","journal-title":"Intern Med"},{"key":"R88-20250619","doi-asserted-by":"crossref","first-page":"e010952","DOI":"10.1161\/JAHA.118.010952","article-title":"Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis.","volume":"8","author":"Rosenthal","year":"2019","journal-title":"J Am Heart Assn"},{"key":"R89-20250619","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ahj.2019.10.003","article-title":"Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS-RCT).","volume":"220","author":"Birnie","year":"2020","journal-title":"Am Heart J"},{"key":"R90-20250619","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.md.0000145367.17934.75","article-title":"Cardiac sarcoidosis: a retrospective study of 41 cases.","volume":"83","author":"Chapelon-Abric","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"R91-20250619","first-page":"509","article-title":"Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases.","volume":"33","author":"Chapelon-Abric","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"R92-20250619","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/kev309","article-title":"Successful use of rituximab in refractory cardiac sarcoidosis.","volume":"55","author":"Krause","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R93-20250619","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"R94-20250619","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00296-006-0215-3","article-title":"The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran\u2019s Affairs patients receiving tumor necrosis factor alpha antagonists.","volume":"27","author":"Cole","year":"2007","journal-title":"Rheumatol Int"},{"key":"R95-20250619","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.amjcard.2019.07.067","article-title":"Infliximab for refractory cardiac sarcoidosis.","volume":"124","author":"Harper","year":"2019","journal-title":"Am J Cardiol"},{"key":"R96-20250619","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.semarthrit.2019.11.004","article-title":"TNF-alpha inhibition for the treatment of cardiac sarcoidosis.","volume":"50","author":"Baker","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R97-20250619","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis.","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R98-20250619","first-page":"2664","article-title":"P4434The first report of significantly improvement of NT-proBNP level in rheumatoid arthritis patients treated with tofacitinib during 12-month follow-up.","volume":"40","author":"Novikova","year":"2019","journal-title":"Eur Heart J"},{"key":"R99-20250619","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","article-title":"EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.","volume":"66","author":"Hoes","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R100-20250619","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/postgradmedj-2014-133219","article-title":"Cardiac sarcoidosis: diagnosis and management.","volume":"91","author":"Dubrey","year":"2015","journal-title":"Postgrad Med J"},{"key":"R101-20250619","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.amjcard.2005.03.059","article-title":"Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis.","volume":"96","author":"Aizer","year":"2005","journal-title":"Am J Cardiol"},{"key":"R102-20250619","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCEP.110.958322","article-title":"Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation.","volume":"4","author":"Mehta","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R103-20250619","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/heartjnl-2015-308708","article-title":"Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.","volume":"102","author":"Birnie","year":"2016","journal-title":"Heart"},{"key":"R104-20250619","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R105-20250619","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1540-8167.2012.02350.x","article-title":"Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis.","volume":"23","author":"Schuller","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R106-20250619","first-page":"244","article-title":"Cardiac sarcoidosis: response to steroids and transplantation.","volume":"6","author":"Valantine","year":"1987","journal-title":"J Heart Transplant"},{"key":"R107-20250619","first-page":"208","article-title":"Heart transplantation for advanced heart failure due to cardiac sarcoidosis.","volume":"32","author":"Theofilogiannakos","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"R108-20250619","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.healun.2007.05.006","article-title":"Outcome of heart transplantation in patients with sarcoid cardiomyopathy.","volume":"26","author":"Zaidi","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R109-20250619","first-page":"367","article-title":"Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids.","volume":"11","author":"Oni","year":"1992","journal-title":"J Heart Lung Transplant"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:03:02Z","timestamp":1750348982000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000400","relation":{},"ISSN":["1061-5377"],"issn-type":[{"type":"print","value":"1061-5377"}],"subject":[],"published":{"date-parts":[[2021,6,14]]}}}